HIND peer analysis
Vyome (HIND) against its competitors: price, today's move, 1-year return and market value side by side.
- HIND's peers: ARMP (Armata Pharmaceuticals), CCCC (C4 Therapeutics), CDXS (Codexis), CGEN (Compugen), IMDX (Insight Molecular Diagnostics), IPHA (Innate Pharma), NVCT (Nuvectis Pharma), OABI (OmniAb).
HIND and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ARMP Armata Pharmaceuticals | $2.98 | -5.99% | -59.18% | $110.83M |
| CCCC C4 Therapeutics | $2.37 | -2.86% | -5.19% | $311.26M |
| CDXS Codexis | $1.05 | -8.70% | -35.19% | $115.08M |
| CGEN Compugen | $1.88 | -4.08% | 17.50% | $178.08M |
| IMDX Insight Molecular Diagnostics | $1.66 | 4.40% | -72.33% | $54.38M |
| IPHA Innate Pharma | $0.94 | -8.75% | -47.78% | $104.99M |
| NVCT Nuvectis Pharma | $19.41 | -2.17% | 225.13% | $667.49M |
| OABI OmniAb | $4.64 | -7.82% | 181.01% | $676.30M |
| TNXP Tonix Pharmaceuticals | $2.39 | -6.46% | -85.73% | $46.35M |
| HIND Vyome | $1.45 | -3.97% | -68.55% | $10.18M |